Skip to main content

Table 2 Summary of Simulation Results

From: Benefits, challenges and obstacles of adaptive clinical trial designs

Design # Patients Expected (N) # of DLT Expected Mean MTD (SD) Prob. of Selecting Correct MTD
"3+3"
TER
15.96 2.8 1.26 (0.33) 0.526
"3+3"
STER*
17.56 3.2 1.02 (0.30) 0.204
CRM(1) 10.60 3.4 1.51 (0.08) 0.984
CRM(2) 13.57 2.8 1.57 (0.20) 0.884
CRM(3) 16.37 2.7 1.63 (0.26) 0.784
  1. * Allows dose de-escalation
  2. CRM(n) = CRM with n patients per dose level; Uniform prior was used.